[1] |
GOEDERT J J.The epidemiology of acquired immunodeficiency syndrome malignancies[J]. Semin Oncol,2000,27(4):390-401.
|
[2] |
BERAL V,PETERMAN T,BERKELMAN R,et al.AIDS-associated non-Hodgkin lymphoma[J]. Lancet,1991,337(8745):805-809.
|
[3] |
MEISTER A,HENTRICH M,WYEN C,et al.Malignant lymphoma in the HIV-positive patient[J]. Eur J Haematol,2018,101(1):119-126.
|
[4] |
ROBBINS H A,PFEIFFER R M,SHIELS M S,et al. Excess cancers among HIV-infected people in the United States[J]. J Natl Cancer Inst,2015,107(4):dju503.
|
[5] |
YANIK E L,TAMBURRO K,ERON J J,et al.Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US,2000 to 2011[J]. Infect Agent Cancer,2013,8(1):18.
|
[6] |
ARZOO K K,BU X,ESPINA B M,et al.T-cell lymphoma in HIV-infected patients[J]. J Acquir Immune Defic Syndr,2004,36(5):1020-1027.
|
[7] |
VOGT S,PATEL M,OMAR T,et al.Molecular diagnostics for AIDS lymphoma diagnosis in south Africa and the potential for other low- and middle-income countries[J]. J Glob Oncol,2018,4:1-6.
|
[8] |
MARKS M A,RABKIN C S,ENGELS E A,et al.Markers of microbial translocation and risk of AIDS-related lymphoma[J]. AIDS,2013,27(3):469-474.
|
[9] |
EPELDEGUI M,VENDRAME E,MARTÍNEZ-MAZA O. HIV-associated immune dysfunction and viral infection:role in the pathogenesis of AIDS-related lymphoma[J]. Immunol Res,2010,48(1-3):72-83.
|
[10] |
IMBEAULT M,OUELLET M,GIGUÈRE K,et al. Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment[J]. J Virol,2011,85(5):2189-2200.
|
[11] |
SHANNON-LOWE C,RICKINSON A B,BELL A I.Epstein-Barr virus-associated lymphomas[J]. Philos Trans R Soc B Biol Sci,2017,372(1732):20160271.
|
[12] |
王迪,冯艳玲. HIV/AIDS 相关淋巴瘤研究进展[J]. 国际肿瘤学杂志,2015,42(6):475-477.
|
[13] |
TANAKA P Y,OHSHIMA K,MATSUOKA M,et al.Epstein-barr viral load is associated to response in AIDS-related lymphomas[J]. Indian J Hematol Blood Transfus,2014,30(3):191-194.
|
[14] |
OHMOTO A,MAESHIMA A M,TANIGUCHI H,et al.Histopathological analysis of B-cell non-Hodgkin lymphomas without light chain restriction by using flow cytometry[J]. Leuk Lymphoma,2015,56(12):3301-3305.
|
[15] |
CHATTERJEE T,SOMASUNDARAM V.Flow cytometric detection of minimal residual disease in B-lineage acute lymphoblastic leukemia by using "MRD lite" panel[J]. Med J Armed Forces India,2017,73(1):54-57.
|
[16] |
YOSHIDA N,ODA M,KURODA Y,et al.Clinical significance of sIL-2R levels in B-cell lymphomas[J]. PLoS One,2013,8(11):e78730.
|
[17] |
WANG L,LIAO D Z,ZHANG J,et al.Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL):a predictive biomarker for treatment efficacy and valuable prognostic factor[J]. Med Oncol,2013,30(4):723.
|
[18] |
ARMITAGE J O.Staging non-Hodgkin lymphoma[J]. CA Cancer J Clin,2005,55(6):368-376.
|
[19] |
郑铁生,鄢盛恺. 临床生物化学检验[M]. 北京:中国医药科技出版社,2015.
|
[20] |
MONTALBÁN C,ABRAIRA V,ARCAINI L,et al. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration,platelet count,high lactate dehydrogenase level and extrahilar lymphadenopathy:development and validation on 593 cases[J]. Br J Haematol,2012,159(2):164-171.
|
[21] |
马肖容,徐燕,王瑾,等. 254例非霍奇金淋巴瘤的临床疗效与预后分析[J]. 中国实验血液学杂志,2016,24(4):1044-1050.
|
[22] |
GASTAUD L,ROSSIGNOL B,PEYRADE F,et al.Role of radiotherapy in the management of non-Hodgkin lymphomas[J]. Cancer Radiother,2016,20(3):236-247.
|
[23] |
杨小芸,沈丽达,龙庭凤,等. 1 326例非霍奇金淋巴瘤临床病理特点分析[J]. 中华肿瘤防治杂志,2016,23(9):605-609.
|
[24] |
BARTA S K,SAMUEL M S,XUE X,et al.Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma[J]. Ann Oncol,2015,26(5):958-966.
|
[25] |
HOFFMANN C J,GALLANT J E.Rationale and evidence for human immunodeficiency virus treatment as prevention at the individual and population levels[J]. Infect Dis Clin North Am,2014,28(4):549-561.
|
[26] |
CRUCIANI M,GATTI G,VACCHER E,et al.Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients[J]. J Antimicrob Chemother,2005,55(4):546-549.
|
[27] |
SOMBOGAARD F,FRANSSEN E J F,TERPSTRA WE,et al. Outcome effects of antiretroviral drug combinations in HIV-positive patients with chemotherapy for lymphoma:a retrospective analysis[J]. Int J Clin Pharm,2018,40(5):1402-1408.
|
[28] |
FOCÀ E,CAVAGLIÀ G,RUSCONI S,et al.Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment:an observational multicentre study[J]. HIV Med,2018,10:1111.
|
[29] |
RIBERA J M,ORIOL A,MORGADES M,et al.Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma:results of a phase Ⅱ trial[J]. Br J Haematol,2008,140(4):411-419.
|
[30] |
GOODMAN A,PATEL S P,KURZROCK R.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas[J]. Nat Rev Clin Oncol,2017,14(4):203-220.
|
[31] |
CHANG E,RIVERO G,PATEL N R,et al.HIV-related refractory Hodgkin lymphoma:a case report of complete response to nivolumab[J]. Clin Lymphoma Myeloma Leuk,2018,18(2):e143-e146.
|
[32] |
PHILIP T,GUGLIELMI C,HAGENBEEK A, et al.Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma[J]. N Eng J Med,1995,333(23):1540-1545.
|
[33] |
RE A,CATTANEO C,ROSSI G.HIV and lymphoma:from epidemiology to clinical management[J]. Mediterr J Hematol Infect Dis,2019,11(1):e2019004.
|
[34] |
刘保池,蔡瑞,朱同玉. 特殊感染外科新理念与新技术[M]. 上海:上海科技教育出版社,2017.
|
[35] |
THOMPSON L D,FISHER M S I,CHU W S,et al. HIV-associated Hodgkin lymphoma:a clinicopathologic and immunophenotypic study of 45 cases[J]. Am J Clin Pathol,2004,121(5):727-738.
|
[36] |
CARBONE A,GLOGHINI A,CARUSO A,et al.The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis[J]. Int J Cancer,2017,140(6):1233-1245.
|
[37] |
AYALA E,CHAVEZ J C,GOMEZ A,et al.Feasibility and efficacy of high-dose chemotherapy and autologous hematopoietic cell transplantation for HIV-associated lymphoma:a single-institution experience[J]. Clin Lymphoma Myeloma Leuk,2018,18(8):548-551.
|